The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.
Besifovir dipivoxil maleate has antiviral efficacy against chronic hepatitis B that is similar to that of tenofovir disoproxil fumarate but with a lower impact on bone and renal safety, as shown in the results of a phase III trial involving Asian patients.
Prof. Rafael R. Castillo, Dr. Hyo Seung Ahn, 20190820000000
Major trials have demonstrated the benefits of beta-blockers in the treatment of hypertension.1 At a recent symposium held during the Asian Paciﬁc Society of Cardiology 2019 Congress in Manila, Philippines, experts discussed the latest guidelines on hypertension treatment, with a focus on the role of the 3rd generation beta-blocker, nebivolol. The symposium was chaired by Dr Dante D. Morales, Clinical Associate Professor at the University of the Philippines College of Medicine, and featured renowned cardiologists Prof Rafael R. Castillo and Dr Hyo Seung Ahn.
The investigational first-in-class attachment inhibitor prodrug fostemsavir (FTR) continues to improve virologic and immunologic response from weeks 48 to 96 in patients with multidrug-resistant HIV-1 who had been heavily treated, according to the BRIGHTE* study presented at IAS 2019.
Dual inhibition of angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A with faricimab induces meaningful and superior visual acuity improvements compared with ranibizumab in patients with diabetic macular oedema, according to the results of the phase II BOULEVARD trial.
Treatment with off-label dose-reduced direct oral anticoagulants (DOACs) leads to reduced effectiveness with no safety benefit among patients with nonvalvular atrial fibrillation (AF), according to a study, suggesting that compliance with per-label dosage may significantly improve outcomes.
The alpha-1 blocker naftopidil facilitated spontaneous expulsion of small ureteral stones in men, highlighting its potential in medical expulsive therapy (MET) for individuals with ureteral stones, a Japanese study has shown.
Patients receiving topiramate to prevent chronic migraines could potentially switch to onabotulinumtoxinA injections to reduce the frequency of their headaches, according to results of the FORWARD* study presented at the recent American Headache Society conference (AHS 2019).
On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.
Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.